Related Experiment Videos
Longitudinal design for phase I clinical trials using the continual reassessment method.
1Department of Biostatistics, Harvard School of Public Health, Boston, MA 02115, USA. anna@hsph.harvard.edu
Controlled Clinical Trials
|January 9, 2001
Summary
This study introduces a longitudinal dose-response model to assess cumulative toxicity in clinical trials. The Bayesian updating mechanism helps determine maximum tolerated doses (MTD) for better trial design.
Area of Science:
- Clinical Trials
- Pharmacokinetics
- Biostatistics
Background:
- Phase I clinical trials primarily estimate the maximum tolerated dose (MTD).
- Assessing cumulative toxicity requires evaluating patient responses to multiple doses.
- Existing methods may not fully capture cumulative toxicity effects over time.
Purpose of the Study:
- To propose a longitudinal dose-response model accounting for cumulative toxicity.
- To develop a Bayesian updating mechanism for individual dose titration.
- To enhance the design of subsequent clinical trial phases (II and III).
Main Methods:
- A longitudinal dose-response model inspired by clearance-rate and Simon et al.'s work.
- A Bayesian updating mechanism for adaptive dose adjustments.
- Application of an extended Continual Reassessment Method (CRM) for MTD selection.
Main Results:
- Simulations demonstrated the proposed model's utility in estimating MTD and cumulative toxicity.
- The Bayesian approach facilitates dynamic dose adjustments.
- The extended CRM effectively selects both individual and group MTDs.
Conclusions:
- The proposed longitudinal model effectively addresses cumulative toxicity in dose-finding studies.
- The Bayesian updating mechanism aids in personalized dose titration.
- This approach provides valuable information beyond MTD for optimizing clinical trial design.